Small-fiber neuropathy (SFN) is a disorder of thinly myelinated Aδ and unmyelinated C fibers. SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life. According to international criteria, the diagnosis is established by the assessment of intraepidermal nerve fiber density and/or quantitative sensory testing.
lead to a diversity of phenotypes, including different pain distributions and presence or absence of autonomic symptoms. This suggests that SFN is part of a clinical continuum. New assessments might contribute to a better understanding of the cellular and molecular substrates of SFN and might provide improved diagnostic methods and trial designs in the future. Identification of the underlying mechanisms may inform the development of drugs that more effectively address neuropathic pain and autonomic symptoms of SFN.
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| INTRODUCTION
Knowledge of small-fiber neuropathy (SFN) has advanced substantially over the last two decades, both at pathophysiological and clinical level. SFN is a condition that selectively involves thinly myelinated Aδ-fibers and unmyelinated C-fibers. It is clinically characterized by neuropathic pain, most frequently described as burning, shooting, and/or prickling. Most cases present with a length-dependent or stocking-glove distribution, 1 although a non-length-dependent pattern of symptoms may also occur. [2] [3] [4] [5] Dysautonomic features may include dry eyes or mouth, orthostatic dizziness, bowel and micturition disturbances, a change of the perspiration pattern, accommodation problems, impotence, diminished ejaculation or vaginal lubrication, hot flushes, and/or cardiac palpitations. 6, 7 In general, pure SFN does not show abnormalities in motor and large sensory nerve fiber function at neurological examination, while hyperalgesia and allodynia frequently accompany nociceptive and temperature sensation loss. 8 In patients with pure SFN, nerve conduction studies (NCSs) reveal no signs of large nerve fiber involvement. In addition, over the last years, there has been increased awareness of chronic itch as a symptom of SFN. [9] [10] [11] [12] Muscle cramps have also been described to be a symptom of SFN, possibly reflecting the location of small nerve fibers as thermoreceptor and nociceptor muscle afferents.
13,14

| EPIDEMIOLOGY
To date, the only epidemiological study in SFN has been performed in the Netherlands. It showed an overall minimum incidence of 12 cases per 100 000 inhabitants per year with long-term persistent complaints. 15 Search Terms: [14] All Clinical Neurology; [97] Ion channel gene defects; [176] All Neuromuscular Disease; [181] Peripheral neuropathy; [224] Neuropathic pain.
Children can also suffer from SFN. Although SFN in children is difficult to diagnose because of the absence of normative data for intraepidermal nerve fiber density (IENFD) in children, several case reports have been published. [16] [17] [18] [19] 2.1 | Quality of life SFN leads to a significant reduction in the overall QoL, 20 at least in part due to pain and autonomic symptoms. Thermal thresholds and reduced IENFD have been reported to correlate with the deterioration of QoL. 21 A significant association was found between pain severity and health status and function. 22 Furthermore, greater adjusted direct and indirect costs were reported at increasing levels of pain in idiopathic SFN. 22 
| Definition and diagnosis
The diagnosis of SFN is made according to a clinically based definition, including symptoms and signs suggestive of SFN and their distribution. 23 The diagnosis can be graded as follows:
Possible: Presence of length-dependent symptoms and/or clinical signs of small-fiber damage;
Probable: Presence of length-dependent symptoms, clinical signs of small-fiber damage, and normal sural NCS;
Definite: Presence of length-dependent symptoms, clinical signs of small-fiber damage, normal sural NCS, and reduced IENFD at the ankle and/or abnormal thermal thresholds. 1, 24, 25 However, this definition only includes length-dependent symptoms, whereas the spectrum of clinical signs has widened from the classical length-dependent SFN to include non-length-dependent patterns. [2] [3] [4] [5] Furthermore, according to this definition, the diagnosis SFN should be considered only in patients with pure or isolated impairment of the Aδ-and C-fibers. Patients with predominant features of SFN and clinical and NCS findings of large sensory fiber dysfunction should be considered to have a mixed (small and large fiber) sensory neuropathy, also described as predominant SFN. A correct classification of SFN is of importance, as it impacts the workup for an underlying condition and the design of clinical trials. 24 
| Assessments
In the past years, new technologies for the assessment of peripheral neuropathies, including SFN, have become available. 26, 27 A number of diagnostic tools are available for the detection of SFN (Table 1) . A distinction can be made in methods that quantify small nerve fibers and methods that test small nerve fiber function. New imaging techniques are likely to impact the diagnostic field in SFN as well.
| Quantification of small nerve fibers 2.4.1 | Skin biopsy
The diagnostic value of skin biopsy with IENFD in patients with clinically suspected SFN has been established, and the method is generally considered the "gold standard" for the diagnosis, although a true gold standard for SFN is lacking. 27, 28 Intra-epidermal nerve fibers (IENF)
are unmyelinated sensory endings with exclusive somatic function that arise from nerve bundles of the subpapillary dermis. 29 They lose the Schwann cell ensheathment as they cross the dermal-epidermal junction [30] [31] [32] and widely express the capsaicin receptor, making them the most distal nociceptors. Skin biopsy is commonly taken with a 3-mm disposable punch, from the lower leg, 10 cm proximal from the lateral malleolus, within the territory of the sural nerve. By means of immunohistochemistry, IENFs are visualized using antibodies against the protein gene product (PGP9.5), a cytoplasmic ubiquitin carboxylterminal hydrolase. The number of fibers crossing the dermal-epidermal junction is quantified, the length of the section is measured, and the linear density of IENF per millimeter is obtained and compared with ageand gender-matched normative values. 28 Recent studies have shown that right-and left-side IENFD overlap in healthy subjects and in patients with length-dependent SFN, and that IENFD is stable when reassessed within a 3-week period that is the time of epidermal renewal, through a follow-up biopsy in the same sensory territory. 33 Disadvantages of skin biopsy are that the analysis is timeconsuming and relatively costly, and that sensitivity is moderate.
Indeed, some patients with symptoms of SFN may have normal IENFD and possibly represent pre-degenerative functional impairment of the nerve fibers. 34 IENFD decreases with aging, 28 and values in upper arm and proximal thigh are significantly higher than in wrist and distal leg, respectively. 35 One study performed to monitor IENFD during disease course in idiopathic SFN found similar rates of decrease in proximal and distal sites of the lower limb. 5 The rates of IENFD decrease over time do not differ between idiopathic SFN, diabetic SFN, and impaired glucose tolerance SFN.
5
IENFD has been reported to be reduced also in other painful conditions, such as Guillain-Barré syndrome, 36 meralgia paraesthestica, 37 notalgia, 38 Ehlers-Danlos syndrome, 39 and fibromyalgia 40 and nonpainful disorders, such as Parkinson disease and related disorders, [41] [42] [43] Key points
• SFN predominantly affects thinly myelinated Aδ-fibers and unmyelinated C-fibers.
• Quality of life in patients with SFN is significantly reduced.
• Reliable diagnostic tests are available to assess function and structure of small nerve fibers, and new screening tools will likely become available.
• Variants in SCN9A, SCN10A, and SCN11A, which encode Na v 1.7, Na v 1.8, and Na v 1.9 sodium channel alpha subunits, are linked to a continuum of pain phenotypes that include SFN.
• A single pain phenotype may be caused by a range of variants, and one specific variant may lead to a range of phenotypes, even within one family.
• Expansion in knowledge on the pathophysiology of SFN will inform the development of new therapies.
amyotrophic lateral sclerosis, [44] [45] [46] critical illness, 47 and peripheral arterial disease. 48 New techniques to determine the IENFD with indirect immunofluorescence, 49 automated PGP9.5 immunofluorescence staining (laboratory developed test), 50 and 3D analysis 51 have been reported. One study investigated the global spatial sampling in order to determine the epidermal nerve fiber length density (ENFLD) taking into account its biologic complexity. 52 Results showed that ENFLD is comparable with IENFD in differentiating between SFN and healthy individuals. 52 In hairy skin, dermal nerve fibers are organized in small bundles.
The bundles located just below the dermal-epidermal junction constitute the subepidermal neural plexus, from which fibers arise to reach the epidermis. Other bundles can be found in the deeper dermis. Most fibers are unmyelinated, and the minority of myelinated fibers are detectable in the upper dermis, usually close to hair follicles or vascular structures . 32 A method for the assessment of dermal nerves by measuring the overall length of the fibers was shown to be reliable in terms of diagnostic yield in patients with pure SFN. 53 The skin is also rich with autonomic nerve fibers, innervating different autonomic structures such as sweat glands and pilomotor muscles. The innervation of dermal autonomic structures can be investigated using markers for adrenergic, noradrenergic, and cholinergic sympathetic fibers and vasodilatory peptidergic fibers. 32 Indeed, several methods have been described to obtain a morphometry of sweat gland and pilomotor muscle innervation. QST is a non-invasive psychophysical method that quantifies the thresholds of sensory perception carried by large and small nerve fibers. 69 QST is considered a diagnostic tool in SFN, 34, 70 and consensus recommendations were provided for clinical use of QST, 71 emphasizing the need of a standardized protocol, adequate equipment, trained staff, and use of normative values. The method of levels (ie, a reaction time-independent method; the subject answers per stimulus whether a warmer or cooler temperature is sensed) has several advantages: there is no effect of stimulus temperature change rate, applicability is possible even in subjects with cognitive impairment and children, and repeatability is comparable or better compared to the method of limits (reaction time-dependent; pushing a button when a change in temperature or pain is sensed). [72] [73] [74] [75] The combination of bilateral warm and cold thresholds of the hands and feet by the levels method probably provides the most optimal sensitivity and specificity.
76 Thermal threshold deterioration was associated with the intensity of pain in peripheral neuropathy. 77 In diabetes without sensory large nerve involvement, a significantly lower IENFD and higher cold perception threshold were found in comparison with controls, irrespective of whether they had symptoms of polyneuropathy or not.
However, a reduction of IENFD was the most frequent abnormal finding in the subgroup of patients with neuropathic symptom, and therefore seemed more sensitive as a diagnostic tool. 78 Furthermore, QST requires the patient to be alert and cooperative, the test cannot discriminate between central and peripheral nervous system diseases, 79 and may be influenced by malingering or other non-organic factors. [80] [81] [82] [83] For all these reasons, QST should be used in relation to the clinical context and in conjunction with other tests, and not alone for the diagnosis of a neurological lesion. 84 
| Microneurography
Microneurography is used to record the activity of C-nociceptors and sympathetic fibers and to test the efficacy of different compounds in blocking abnormal on-going activity in both animal models and in patients. 85 The use of microneurography is increasing in disorders affecting the peripheral nervous system. [86] [87] [88] [89] However, its application in clinical practice remains limited due to the technical challenges, the amount of time needed to perform the examination, the small number of nerve fibers that can be studied in any given patient, and the test awaits validation of diagnostic value. 90 
| Nociceptive-evoked potentials
Nociceptive-evoked potentials can be used to investigate the conduction properties of small nerve fibers in a fashion not dependent on patients' cooperation and attention. 91 These nociceptive-evoked potentials can be generated by either radiant heat (laser-evoked potentials, LEPs) or contact heat (contact heat-evoked potentials, CHEPs). Both LEPs and CHEPs are based on selective of Aδ-and C-fiber activation, whereas induction of pain-related-evoked potentials (PREPs) involves the preferential stimulation of Aδ-fibers. 92 Skin denervation induced by topical capsaicin causes the decrease of LEP amplitude. 93 LEPs are a validated technique to investigate the neural bases of nociception. 94, 95 LEP amplitudes correlate with the reported intensity of perceived pain, 96 and negatively with age. 97 Moreover, it is modulated by opioids 98 and pain expectation. 99, 100 Comparable to QST, LEPs cannot discriminate the site of pathology (peripheral nerves, plexus, roots, spinal cord, or brainstem) 101 and should therefore also be considered a supportive tool for diagnosing SFN. 
| Magnetic resonance imaging
Non-invasive imaging techniques, such as functional magnetic resonance imaging (fMRI), are used to measure neuronal activity in humans in order to study regional activation in various parts of the brain in chronic pain states. The advantage of fMRI is the ability to ascribe function to specific brain regions. The resolution of fMRI images has become more detailed with increasing magnet strength.
Skin denervation has been associated with abnormal recruitment of pain-related regions in the brain, 113 especially in diabetic neuropathic pain 114, 115 suggesting altered patterns of activation of the brain in painful neuropathy. Volume reduction was most notable in painprocessing regions, particularly the bilateral anterior cingulate cortices, which was associated with a greater depletion of IENF. 116 However, whether a specific activation pattern can be seen depends on many factors, such as type of brain imaging modality. 117 It is conceivable that a particular type of pain (stimulus) may enhance a specific pain brain pattern, but patient-specific factors (ie, gender, genetic, and epigenetic factors) may influence the pain activation network. [118] [119] [120] Psychological modulation as well as chronicity of pain may influence the activation network, and should therefore be taken into account.
121-126
| Autonomic testing
Changes in peripheral autonomic nervous system function may be an early manifestation in SFN. 127 Dysfunction of the sudomotor system may result in an increase or decrease in sweat production, resulting in disturbances of thermoregulation. Traditional measurements of sudomotor function include thermoregulatory sweat testing, quantitative sudomotor axon-reflex testing (QSART), silicone impressions, quantitative direct and indirect axon-reflex testing, and the sympathetic skin response (SSR). 128 
| Thermoregulatory sweat testing
Thermoregulatory sweat testing is performed by increasing the ambient room temperature which in turn raises blood and skin temperature. The degree and extent of sweat production are then visualized with an indicator dye. 128 The test is time-consuming, requires special equipment, and special preparation and treatment of the patient, and is therefore only performed in highly specialized centers, limiting the clinical applicability. 140 Therefore, the value of Sudoscan as a diagnostic tool for SFN still needs to be determined.
| Neuropad
Another recently developed test, the Neuropad was introduced to measure sweat production based on the color change of a cobalt II compound. 141 Moderate sensitivity and specificity (68% and 49%, respectively) were found using the warm perception threshold as a reference method, and these were enhanced when the corneal nerve fiber length (CNFL) was used as a reference method (83% and 80%, respectively). The contribution of this test to the diagnosis SFN needs to be established.
| Stimulated skin wrinkling
Stimulated skin wrinkling (SSW) is a test for sympathetic function based on changes of dermal arteriovenous tissue vasoconstriction of the digits. A negative digit pulp pressure will occur after a warm water bath for 30 minutes. Wrinkling would occur when epidermal skin is drawn down unevenly, because of its varying tautness. 142 The eutectic mixture of local anesthetics (EMLA©) cream can also be used as a vasoconstrictive factor with similar results. [143] [144] [145] In clinical practice, SSW is usually performed in the hands and graded using a published 5-point scale. [146] [147] [148] Foot skin wrinkling is hardly ever performed, as wrinkling is poor because of higher sympathetic nerve activity to the lower limbs. 149 Reduced SSW was found in patients with diabetic neuropathy [150] [151] [152] and in idiopathic SFN. [146] [147] [148] However, the value of SSW as a diagnostic tool is currently limited. Even in patients with a known possible etiology, additional underlying causes can be found in 27% of patients. 157 It is therefore recommended to screen patients with SFN at least for autoimmune diseases, diabetes mellitus including glucose intolerance, vitamin B12 deficiency, and sodium channel gene variants, even when they already have a potential underlying condition at referral.
| Outcome measures
| Voltage-gated sodium channelopathies in SFN
Voltage-gated sodium channels play an essential role in regulating the excitability of nociceptive primary afferent neurons. Three voltagegated sodium channels, Na V 1.7, Na V 1.8, and Na V 1.9, encoded by genes SCN9A, SCN10A, and SCN11A, are preferentially expressed in peripheral neurons and are known to play a role in human pain disorders. 162 Gain-of-function SCN9A variants have been described in three painful human pain conditions: inherited erythromelalgia (IEM), paroxysmal extreme pain disorder (PEPD), and SFN. By contrast, congenital insensitivity to pain (CIP) is associated with autosomal recessive lossof-function SCN9A variants. Increased understanding of the pathophysiological mechanisms underlying sodium channelopathies 163, 164 paved the way for the development of isoform-selective blockers as a targeted treatment modality. 175, [188] [189] [190] and children. 178, 191 This left shift of activation enhances excitability, intuitively explaining the pain phenotype. 177, 192, 193 The phenotype, however, can be complex and variable, 188, [194] [195] [196] [197] [198] [199] even within families carrying the same variant.
170
The I234T-variant, which causes IEM-like pain phenotype, exhibits a complex phenotype that includes automutilation 199, 200 and bilateral congenital corneal anesthesia. 201 These findings, which suggest both gain of function and loss of function at the clinical level for patients carrying this variant, are explained by the unusually large hyperpolarization of activation of the mutant channel, which produces a massive depolarization in the resting potential of some dorsal root ganglion (DRG) neurons, thus silencing them. 202 Several variants have been reported without functional testing. 203, 204 Recently, a Na v 1.8 variant has been linked to a syndrome with clinical characteristics similar to IEM. from autonomic dysfunction leading to poor feeding and reflux, vomiting, tonic attacks, breath holding spells, and bradycardia that sometimes requires insertion of a pacemaker. PEPD is caused by gain-offunction Na V 1.7 variants that mostly result in impaired fast inactivation. So far, 10 variants in Na V 1.7 are known that cause PEPD. [206] [207] [208] [209] [210] [211] [212] It is thought that the variant induces a depolarizing shift of steadystate fast inactivation, hampering channel closure during action potential electrogenesis.
2.10.3 | Na V 1.7 in channelopathy-associated insensitivity to pain
Patients with CIP do not perceive physical pain (OMIM 243000). The difference between sharp and dull and hot and cold is felt, but the pain awareness is absent. Young children with CIP may accrue mouth or finger wounds due to repeated self-biting, may also experience multiple burn-related injuries, and may injure bones and joints without experiencing pain. They also have a complete loss of the sense of smell (anosmia). SCN9A homozygous missense and deletion variants have been described in these patients, who do not produce functional Nav1.7 channels, and has been linked to the absence of pain perception. [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] Partial deletion of pain perception was also described. 224 The clinical phenotype of patients with reduced pain Immunological causes: Sarcoidosis, Sjogren disease, coeliac disease, other autoimmune diseases, and abnormal immunological laboratory findings (antinuclear antibodies, antineutrophil cytoplasmic antibodies, monoclonal gammopathy, soluble interleukin-2 receptor, antitissue transglutaminase, and antiextractable nuclear antigen antibodies). MGUS, monoclonal gammopathy of undetermined significance; SFN, small-fiber neuropathy sensibility due to Na v 1.9-variants is different than Na v 1.7-associated CIP. [225] [226] [227] Large hyperpolarizing shifts in the voltage dependence of activation in the mutated Na V 1.9 channels in these cases are associated with insensitivity to pain. This evokes a massive degree of membrane depolarization that renders DRG neurons hypoexcitable. 228 2.10.4 | Na V 1.7 in SFN
The first gain-of-function variants in Na V 1.7 that change the properties of the channel and the excitability of DRG neurons were described in 2012 in skin biopsy-and QST-confirmed idiopathic SFN. 229 Unexpectedly, while there is a strong correlation between genotype and phenotype for many mutations, some patients carrying 2.10.6 | Na V 1.9 in SFN Na V 1.9 is preferentially expressed in small-diameter DRG neurons, trigeminal ganglion neurons, and intrinsic myenteric neurons. 246 Several human pain disorders have been linked to dominant gain-of-function Na V 1.9 variants, including early-onset pain in distal extremities, [247] [248] [249] cold-aggravated pain, 250 and SFN. 251, 252 The expression of Na V 1.9 in myenteric neurons can explain the gastrointestinal symptoms reported by patients harboring SCN11A variants. 247 Finally, gain-offunction variants in Na V 1.9 have been reported in patients with a complex clinical syndrome that includes insensitivity to pain. 226, 227, 253 The loss of pain sensibility in these cases arises from a massive depolarization of DRG neurons that inactivates the sodium channels in these cells and reduces their excitability. 228 
| Overlap between pain disorders
With the description of painful SFN caused by Na V 1.7 variants, it has become clear that the phenotype of Na V 1.7 variants expands, and that the boundaries between these phenotypes are not always distinct ( Figure 2 ). Clinically, burning pain with a stocking-glove distribution is a common characteristic in SFN but is also seen in IEM. 190, 229 Facial
The triangle of SCN9A-related pain disorders. Modified from Hoeijmakers, thesis: SFN and sodium channels: a paradigm shift, 2014, chapter 9, Figure 1 . 254 IEM, inherited erythromelalgia; PEPD, paroxysmal extreme pain disorder; SFN, small-fiber neuropathy and diffuse or widespread pain can be seen in SFN and PEPD, 208, 229, 231 and also in IEM. 169 Although this suggests that the function of small nerve fibers is equally impaired, IEM is usually not characterized by a loss of epidermal nerve fibre density. 255 Reddening of the skin can occur in both IEM and PEPD and, to a lesser extent, in SFN. One study suggested that the activity of mutant Na v 1.7 channels in smooth muscle cells and sympathetic fibers innervating skin vessels may contribute to this phenomenon. 256 Mixed phenotypes of IEM and SFN, IEM and PEPD, or SFN and PEPD associated with one variant have been described. Among SCN9A variants, the R185H has been found in patients diagnosed with either PEPD 257 or SFN. 229 The A1632E variant has been found in a patient with a mixed phenotype of IEM and PEPD, and causes a mixed physiological change in channel function, of hyperpolarized activation and impaired fast inactivation of the channel, which are typically associated with IEM and PEPD, respectively. 258 The heterozygous L245V variant that was found in a large family with IEM did not affect channel activation, but instead resulted in incomplete fast inactivation and a small hyperpolarizing shift in steady-state slow inactivation, which is more characteristic for PEPD. 259 Overall at the structural level, most IEM variants tend to be located within the domains I and II of the protein, while PEPD variants are commonly located in the domains III and IV. The structural dichotomy, while not present in every case, parallels the biophysical effects of the two types of variants. 260 
| Electrophysiology and pathogenicity of voltage-gated sodium channels variants
Although we know that some variants in sodium channels Na V 1.7, Na V 1.8, and Na V 1.9 can cause pain disorders, it is important to discriminate disease-causing variants from disease-contributing variants and variants of uncertain significance. 236 IEM and PEPD are due to rare, high impact, fully penetrant variants in Nav1.7. The frequency of specific variants is still low in the SFN population, and one could argue whether these variants can be considered risk factors or variants contributing to the disease, but not causing the disease. The clinical utility of in-silico mutation-prediction programs is at best moderate, because these algorithms do not always accurately predict changes in channel function. 236 Consensus has been reached that newly described gene challenging. 262 At present, treatment of neuropathic pain is often disappointing, leading overall to pain relief of about 50% in only one half of the patients, and the drug often has to be discontinued due to unpredictable side effects. The recent genetic and functional findings in SFN may pave the way for the development of new analgesics through both pharmacogenomic targeting of existing medication 263, 264 and the development of a new generation of specific sodium channel blockers. [165] [166] [167] As pain is a complex symptom, in which not only physical factors but also psychological, neurophysiological, socioeconomic, and cultural aspects may influence the experience and continuation of pain, a multidisciplinary approach in line with the biopsychosocial model is required in optimizing treatment for the individual patient. 265 Physical therapy modalities and rehabilitation techniques are important options. 266 Moreover, supervised exercise in patients with metabolic syndrome showed an increased cutaneous regenerative capacity, suggesting potential benefits of peripheral nerve function. 
ACKNOWLEDGEMENTS
Part of our research is funded by the European Union seventh Framework Programme (grant n 602273).
Author Contributions
All authors contributed equally to researching data for the article, discussion of content, writing the article, and to the editing and review of the manuscript before submission.
ORCID
Giuseppe Lauria
https://orcid.org/0000-0001-9773-020X
